Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $42.07M | $36.53M | $24.86M | $37.04M | $7.66M | $24.65M |
| Cost of Revenue | N/A | N/A | N/A | N/A | $1.63M | $32.27M |
| Gross Profit | $42.07M | $36.53M | $24.86M | $37.04M | $6.03M | $-7.63M |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 78.77% | -30.93% |
| Operating Expenses | $187.66M | $150.70M | $135.93M | $95.23M | $58.23M | $7.54M |
| Operating Income | $-145.59M | $-114.17M | $-111.07M | $-58.19M | $-52.20M | $-15.16M |
| Operating Margin | -346.09% | -312.57% | -446.79% | -157.09% | -681.82% | -61.51% |
| Net Income | $-130.30M | $-101.74M | $-108.18M | $-58.23M | $-51.97M | $-14.10M |
| Net Margin | -309.73% | -278.54% | -435.14% | -157.21% | -678.84% | -57.18% |
| EPS (Basic) | $-1.19 | $-1.08 | $-1.23 | $-0.94 | $-1.62 | $-1.57 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |